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Abstract
Introduction: We report the impact of canakinumab, a fully human anti-interleukin-1β monoclonal antibody, on
inflammation and health-related quality of life (HRQoL) in patients with difficult-to-treat Gouty Arthritis.
Methods: In this eight-week, single-blind, double-dummy, dose-ranging study, patients with acute Gouty Arthritis
flares who were unresponsive or intolerant to - or had contraindications for - non-steroidal anti-inflammatory drugs
and/or colchicine were randomized to receive a single subcutaneous dose of canakinumab (10, 25, 50, 90, or 150
mg) (N = 143) or an intramuscular dose of triamcinolone acetonide 40 mg (N = 57). Patients assessed pain using a
Likert scale, physicians assessed clinical signs of joint inflammation, and HRQoL was measured using the 36-item
Short-Form Health Survey (SF-36) (acute version).
Results: At baseline, 98% of patients were suffering from moderate-to-extreme pain. The percentage of patients
with no or mild pain was numerically greater in most canakinumab groups compared with triamcinolone
acetonide from 24 to 72 hours post-dose; the difference was statistically significant for canakinumab 150 mg at
these time points (P < 0.05). Treatment with canakinumab 150 mg was associated with statistically significant lower
Likert scores for tenderness (odds ratio (OR), 3.2; 95% confidence interval (CI), 1.27 to 7.89; P = 0.014) and swelling
(OR, 2.7; 95% CI, 1.09 to 6.50, P = 0.032) at 72 hours compared with triamcinolone acetonide. Median C-reactive
protein and serum amyloid A levels were normalized by seven days post-dose in most canakinumab groups, but
remained elevated in the triamcinolone acetonide group. Improvements in physical health were observed at seven
days post-dose in all treatment groups; increases in scores were highest for canakinumab 150 mg. In this group,
the mean SF-36 physical component summary score increased by 12.0 points from baseline to 48.3 at seven days
post-dose. SF-36 scores for physical functioning and bodily pain for the canakinumab 150 mg group approached
those for the US general population by seven days post-dose and reached norm values by eight weeks post-dose.
Conclusions: Canakinumab 150 mg provided significantly greater and more rapid reduction in pain and signs and
symptoms of inflammation compared with triamcinolone acetonide 40 mg. Improvements in HRQoL were seen in both
treatment groups with a faster onset with canakinumab 150 mg compared with triamcinolone acetonide 40 mg.
Trial registration: clinicaltrials.gov: NCT00798369.
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Gouty arthritis is a common inflammatory arthritis caused
by the deposition of monosodium urate (MSU) crystals in
joints [1,2]. The deposition and dissolution of the MSU
crystals themselves depends on serum urate levels. MSU
crystals induce secretion of interleukin-1b (IL-1b), a proin-
flammatory cytokine that mediates the inflammation that
is characteristic of Gouty Arthritis flares and that may
remain present between flares [3,4]. There is evidence to
suggest that IL-1b may also contribute to joint destruction
in Gouty Arthritis [5-7]. Current treatments to control the
pain and inflammation associated with acute flares include
non-steroidal anti-inflammatory drugs (NSAIDs), colchi-
cine, and corticosteroids [8,9]. However, these treatments
are not always effective [10]. In addition, many patients
with Gouty Arthritis have underlying comorbidities such
as cardiovascular disease, diabetes mellitus, hypertension,
liver and renal disease, or gastrointestinal problems, which
restrict treatment options or necessitate modifications in
the management of Gouty Arthritis [8,11-14]. Further-
more, patients with comorbidities often experience fre-
quent flares. Therefore, there is a need for new therapies
to provide effective pain relief in these patients with diffi-
cult-to-treat Gouty Arthritis.
Without adequate treatment, Gouty Arthritis can pro-
gress into a chronic, deforming, and physically disabling
disease through the development of disfiguring tophi, joint
destruction, and persistent pain [15,16]. Pain and impaired
physical functioning can have a major impact on a patient’s
health-related quality of life (HRQoL). Results from several
observational studies in patients experiencing frequent
Gouty Arthritis flares reported HRQoL scores considerably
lower than those for men of a similar age in the US general
population [17-21]. In addition, patients who experienced
more Gouty Arthritis flares and had a greater number of
joints involved had a particularly poor HRQoL [18,19].
However, there are no published data regarding the impact
of acute flares on HRQoL. The unpredictability of Gouty
Arthritis flares further accentuates the impact of this dis-
ease on patients. If inappropriately managed, Gouty Arthri-
tis represents a considerable economic burden through lost
productivity and the cost of treatment, especially in
patients with frequent flares [22,23].
Results of a recent multicenter phase 2 study have
shown that canakinumab, a fully human anti-IL-1b
monoclonal antibody, can produce rapid reductions in
pain in patients with Gouty Arthritis who are unrespon-
sive or intolerant to, or contraindicated for NSAIDs
and/or colchicine, and can significantly reduce the risk
of recurrent flares [24]. The canakinumab 150 mg dose
was found to be superior to triamcinolone acetonide
40 mg on all efficacy measures reported [24]. Here we
report further results from this study which confirm the
superiority of the 150 mg dose over triamcinolone
acetonide including effects on pain assessed using the
Likert scale, clinical signs and markers of inflammation
(C-reactive protein (CRP) and serum amyloid A protein
(SAA)), as well as improvements in HRQoL measures
(36-item Short-Form Health Survey (SF-36) and Health
Assessment Questionnaire (HAQ)).
Materials and methods
Study design
This was an adaptive single-dose, single-blind, active-
controlled study. The study was approved by each local
independent ethics committee. It was performed in con-
cordance with the ICH Harmonised Tripartite Guide-
lines for Good Clinical Practice and the ethical
principles of the Declaration of Helsinki, and all patients
provided written informed consent. Patients were
screened at the time of an acute Gouty Arthritis flare;
eligible patients were subsequently randomized and
received either canakinumab at one of five doses (10,
25, 50, 90, or 150 mg) by subcutaneous (s.c.) injection
and saline by intramuscular (i.m.) injection, or i.m.
triamcinolone acetonide (40 mg) and a s.c. placebo
injection on day 1. Randomization was carried out by
means of an interactive voice response system. Patients
were not informed of their assigned treatment during
the study; wherever possible, treatment was adminis-
tered by an unblinded pharmacist, nurse or physician
w h ow a sn o ti n v o l v e di na n yo ft h es t u d ya s s e s s m e n t s ,
allowing the investigator tob eb l i n d e dt ot r e a t m e n t .
This was the case for 161 of the 200 patients (80.5%)
who thus received double-blind treatment.
Patients recorded pain intensity at pre-specified time
points (using a Likert scale and visual analog scale
(VAS)) and their use of rescue medication during the
first seven days of the study. Patients who had difficulty
tolerating their pain after the six-hour post-dose pain
assessments could take rescue medication consisting of
prednisone to a maximum dose of 30 mg once daily for
up to five days and acetaminophen 500 mg (up to a
maximum of 1 g/dose or 3 g/day) and/or codeine 30 mg
(up to a maximum of 30 mg/dose or 180 mg/day) as
needed during the first seven days, but not within four
hours before a pain assessment. Patients returned to the
study center three days (72 hours after study drug
administration) seven days, four weeks, and eight weeks
post-dose for efficacy and safety assessments. Patients
were not informed of their assigned treatment during
the study; physicians were not blinded to treatment.
Patients
Key inclusion criteria were: patients aged 18 to 80 years
with a history of at least one previous Gouty Arthritis
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1977 preliminary criteria for the classification of acute
arthritis of primary gout; presence of an acute Gouty
Arthritis flare for no longer than five days; baseline pain
intensity ≥50 mm on the 0 to 100 mm VAS; unresponsive
or intolerant to, or contraindicated for NSAIDs and/or
colchicine; body mass index (BMI) ≤40 kg/m
2. Unrespon-
siveness and intolerance to NSAIDs and/or colchicine
and contraindication for NSAIDs and/or colchicine were
based on physicians’ assessment. Patients on urate-lower-
ing therapy (ULT) were required to be on a stable dose
and schedule, with no changes in therapy for four weeks
before randomization, and were to be expected to remain
on a stable regimen during study participation.
Exclusion criteria included: use of prohibited medica-
tions before screening (any ibuprofen in the 4 hours
before screening (day 1) or >400 mg in the 8 hours before
screening; any acetaminophen in the 4 hours before
screening or >1 g in the 24 hours before screening; any
aspirin in the 4 hours before screening or >600 mg in the
24 hours before screening; any over-the-counter analgesic
aspirin-based or acetaminophen-based combination med-
ication tablets in the 4 hours before screening or >2
tablets in the 24 hours before screening; any diclofenac in
the 8 hours before screening or >50 mg in the 24 hours
before screening; any naproxen in the 12 hours before
screening or >500 mg in the 24 hours before screening;
cyclo-oxygenase-2 inhibitors in the 48 hours before
screening; other NSAIDs in the 24 hours before screen-
ing; systemic corticosteroids in the 24 hours before
screening (a dose <10 mg of prednisolone or equivalent
was permissible in the 24 hours before screening); intra-
articular corticosteroids in the 4 weeks before screening;
more than one dose of 0.6 mg colchicine in the 24 hours
before screening, if not on a stable dose regimen; anakinra
in the 24 hours before screening; rilonacept in the week
before screening; other investigational drugs or experi-
mental biologic treatment, other than anakinra or rilona-
cept, in the 30 days (or 3 months for monoclonal
antibodies) or five half-lives before screening, whichever
was longer, or as instructed by local regulations; any
tumor necrosis factor inhibitor in the 3 months before
randomization; rheumatoid, infectious/septic or other
inflammatory arthritis; severe renal function impairment;
drug allergies; idiopathic thrombocytopenic purpura; con-
traindication to i.m. injections; donation or loss of ≥400
mL of blood in the 8 weeks before dosing; live vaccination
in the 3 months before the start of the study; known pre-
sence or suspicion of active or recurrent infection at
enrolment; evidence of active pulmonary disease; require-
ment for administration of antibiotics against latent
tuberculosis; risk factors for tuberculosis; any surgical or
underlying hepatic, hematological, pulmonary, infectious
or gastrointestinal condition that compromised the
patient’s immune system and/or placed them at unaccep-
table risk if they received immunomodulatory therapy;
long QT syndrome or QTc >450 ms for men and >470
ms for women at screening or baseline; significant medi-
cal problems, e.g. uncontrolled hypertension, uncon-
trolled diabetes, thyroid disease, history of malignancy of
any organ system within the preceding 5 years; pregnant
or nursing (lactating) women; women who were physiolo-
gically capable of becoming pregnant unless they were
using an acceptable method of contraception; familial and
social conditions rendering regular medical assessment
impractical.
Assessment and definition of response
Study assessments made at baseline and each subsequent
scheduled clinic visit (72 hours, 7 days, 4 weeks, and 8
weeks post-dose) included: patient assessment of pain
intensity using a 5-point Likert scale (recording no (0),
mild (1), moderate (2), severe (3), and extreme (4) pain)
and a VAS (ranging from no pain (0 mm) to unbearable
pain (100 mm)); the physician’s assessment of tenderness,
swelling, and erythema in the target joint; and physician
and patient global assessments of response to treatment.
In addition, blood samples were collected for assessment
of blood chemistry (including CRP and SAA levels)
and hematology. Adverse events (AEs) were reported
throughout the study and physicians assessed local toler-
ability at sites of s.c. and i.m. injections at each scheduled
visit. Blood samples were assessed for anti-canakinumab
antibodies at baseline and at eight weeks post-dose using
a validated Biacore
® binding assay (Biacore International
AB, Uppsala, Sweden) [25].
Pain intensity scores (according to the Likert scale and
VAS) were recorded by patients in their diaries at 6,
12, 24, and 48 hours, and 4, 5, and 6 days post-dose,
and during scheduled clinic visits at 72 hours, 7 days,
4 weeks, and 8 weeks post-dose. Physicians assessed
inflammation in the target joint using the following ten-
derness and swelling scales: tenderness rated as none,
‘no pain’;m i l d ,‘pain’; moderate, ‘pain and winces’;
severe, ‘pain; winces and withdraws’;a n ds w e l l i n gr a t e d
as none, ‘no swelling’; mild, ‘palpable’; moderate, ‘visible’;
and severe, ‘bulging beyond the joint margins’. Erythema
was assessed as ‘absent’, ‘present’ or ‘not assessable’.
Physicians rated response to treatment as ‘very good’,
‘good’, ‘fair’, ‘poor’,o r‘very poor’; and patients rated
response to treatment as ‘excellent’, ‘good’, ‘acceptable’,
‘slight’ or ‘poor’. Subsequent flares were identified
from patient-reported signs and symptoms of Gouty
Arthritis.
HRQoL instruments
HRQoL was assessed at baseline, and at seven days and
eight weeks post-dose using the SF-36 (acute version 2)
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were exploratory endpoints.
36-item Short-Form Health Survey
SF-36 measures the impact of disease on overall quality
of life and consists of eight individual domains that can
be grouped to derive a physical component summary
(PCS) (composed of physical functioning, role-physical,
bodily pain and general health) and a mental component
summary (MCS) (composed of vitality, social function-
ing, role-emotional and mental health) [26]. Scores
range from 0 to 100, where 0 represents the worst pos-
sible health and 100 is perfect health [27]. This instru-
ment has been validated for use in patients with Gouty
Arthritis [28,29]. This study employed the acute (one-
week) recall version of SF-36 version 2 [30]. This more
recently developed acute form of the 36-item question-
naire was designed for applications in which health sta-
t u si sm e a s u r e dw e e k l yo rb i w e e k l y .I tw a sc r e a t e db y
changing the recall period for six of the eight scales
[Role-Physical (RP), Bodily Pain (BP), Vitality (VT),
Social Functioning (SF), Role-Emotional (RE) and Men-
tal Health (MH)] from “the past four weeks” to “the
past week”. The other two scales, Physical Functioning
(PF) and General Health (GH), do not have a recall per-
iod; the items and instructions for these scales are iden-
tical across acute and standard forms. This acute
version of SF-36 has been shown to be more sensitive to
recent changes in health status. Results were plotted as
spidergrams, as recommended by Strand et al. [31].
Health Assessment Questionnaire
The HAQ assesses a patient’s physical ability, functional
status, and quality of life through 20 questions concern-
ing difficulty in performing eight common activities of
daily living [32,33]. Patients choose from four response
categories with scoring of 0 to 3, ranging from ‘without
any difficulty’ (0) to ‘unable to do’ (3).
Statistical analysis
In this paper we report the results of secondary efficacy
endpoints with respect to reduction of signs and symp-
toms of inflammation during flares and exploratory end-
points regarding HRQoL. Results for the primary endpoint
and for other secondary endpoints have been reported
previously and are not included in this paper [24].
Differences in the reduction in pain (Likert scale) were
analyzed using an analysis of covariance with treatment
group, baseline Likert scale score, and baseline BMI as
covariates, while differences in joint tenderness, swelling
and erythema were assessed using proportional odds
regression with treatment group, baseline physician
assessment, and baseline BMI as covariates. Differences
in physician and patient global assessments were
assessed using proportional odds regression with treat-
ment group and BMI at baseline as covariates. The
percentage of patients with no/mild pain was analyzed
using a logistical regression model with baseline Likert
score and BMI as covariates. The percentage of patients
with normalized CRP and SAA concentration values
was analyzed using a logistical regression model with
baseline CRP/SAA concentration value and BMI as cov-
ariates. Mean and standard deviation (SD) were deter-
mined for SF-36 PCS, MCS and subscale scores.
Descriptive analyses are provided for HAQ scores. All
covariates were defined ap r i o r i .N oa d j u s t m e n tw a s
made for multiplicity.
All efficacy end points were analyzed using the full
analysis set (i.e. all randomized patients who received
study drug had at least one post-baseline VAS assess-
ment) and safety assessments were based on the safety
analysis set (i.e. all randomized patients who received
study drug and had at least one post-baseline safety
assessment).
Results
Between November 2008 and May 2009, 200 patients
from 89 centers in 11 countries (Argentina, Belgium,
Canada, France, Germany, Poland, Russia, Switzerland,
T u r k e y ,t h eU Ka n dt h eU S A )w e r ee n r o l l e da n d1 9 1
patients completed the study (Figure 1). The demo-
graphic and baseline disease characteristics of patients
enrolled on this study were generally well balanced
across treatment groups and have been described pre-
viously [24] (for details see Supplementary table S1 in
Additional file 1). Most patients had had multiple acute
Gouty Arthritis flares in the preceding 12 months
(mean number of flares in each treatment group, 3.9 to
6.8). There was a baseline imbalance in pain intensity
between groups, with mean scores being lowest in the
canakinumab 150 mg group; the imbalance was signifi-
cant for VAS score (P = 0.005), but not for the Likert
scale scores. Physician baseline assessments of joint ten-
derness, swelling, and erythema were generally well
balanced among treatment groups.
Pain reduction
At baseline, 98% of patients were suffering from moder-
ate, severe, or extreme pain in the target joint (Likert
assessment) (see Supplementary table S1 in Additional
file 1). Reductions in the percentage of patients with
moderate/severe/extreme pain were seen in all treat-
ment groups from six hours post-dose onwards. The
percentage of patients with no or mild pain was numeri-
cally greater in most canakinumab groups compared
with triamcinolone acetonide from 24 to 72 hours post-
dose and the difference was statistically significant
for the 150 mg group at these time points (P <0 . 0 5 )
(Figure 2). The reduction in pain intensity from baseline
was also significantly greater for canakinumab 150 mg
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post-dose to 7 days post-dose (Figure 2).
Reduction in signs of inflammation
Physician and patient assessments
At baseline, most patients had moderate or severe
tenderness (85% of patients), moderate or severe joint
swelling (85% of patients), and/or erythema (83% of
patients). All treatments reduced visible signs of inflam-
mation in the target joint by 72 hours post-dose (the
first assessment). At this time point, patients treated
with canakinumab 150 mg had a statistically significant
lower score on the Likert scale for tenderness and for
swelling compared with patients receiving triamcinolone
acetonide and the difference between treatments
remained statistically significant at seven days post-dose
(Figures 3 and 4). Erythema was absent in 74.1% of
patients receiving canakinumab 150 mg and 69.6% of
patients receiving triamcinolone acetonide at 72 hours
post-dose and in 96.3% (canakinumab 150 mg) and
83.9% (triamcinolone acetonide) of patients at seven
days post-dose. At 72 hours post-dose canakinumab 150
mg was also associated with statistically significant bet-
ter responses to treatment according to patient global
self-assessment and physician global assessment com-
pared with patients treated with triamcinolone acetonide
(Figure 4).
Inflammatory markers
At baseline, CRP levels and SAA levels were above the
upper limit of the normal range in the majority of
patients (CRP, 79.2%; SAA, 64.0%). At seven days post-
dose, CRP levels were normalized (≤3.0 mg/L) in 46.4 to
72.4% of patients in the canakinumab groups vs 41.1%
in the triamcinolone acetonide group (Table 1). For the
canakinumab 150 mg group, the percentage of patients
with normalized CRP levels was significantly greater
than that in the triamcinolone acetonide group at seven
days, four weeks, and eight weeks post-dose (P < 0.05).
SAA levels were normalized (≤6.7 mg/L) in 63.0 to
75.9% of canakinumab-treated patients compared with
44.6% of patients receiving triamcinolone acetonide at
seven days post-dose (Table 1). From this time point
onwards the percentage of patients with normalized
SAA levels was numerically greater for all canakinumab
groups compared with triamcinolone acetonide, but the
difference did not reach statistical significance for most
doses or time points (Table 1).
HRQoL measures
36-item Short-Form Health Survey (acute version 2)
At baseline, mean SF-36 PCS and mean MCS were well
below those of the US general population: PCS, 30.0 to
36.1 (US general population, mean ± SD 50.0 ± 10.0)
and MCS, 42.9 to 48.2 (US general population, mean ±
Figure 1 Study disposition. Number of patients who entered and completed the study and reasons for discontinuation.
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vidual SF-36 domains were much lower than those for
the general US population: physical functioning, 31.1 to
41.5 (US general population, 84.2); role-physical, 31.3
to 53.0 (US general population, 80.9); bodily pain, 23.5
to 36.0 (US general population, 75.2); general health,
53.5 to 65.4 (US general population, 71.9); vitality, 41.3
to 53.9 (US general population, 60.9); social functioning,
47.7 to 62.5 (US general population, 83.3); role-emo-
tional, 54.6 to 66.5 (US general population, 81.3); mental
health, 58.1 to 67.9 (US general population, 74.7).
All aspects of physical health improved in all treat-
ment groups over the first seven days post-dose, as
reflected in increases in PCS, and were greatest for the
canakinumab 150 mg group. In this group, mean (± SD)
PCS increased by 12.0 ± 10.0 points from baseline to
48.3 ± 8.6 at seven days post-dose and exceeded that of
the US general population by eight weeks post-dose,
having a score of 52.8 ± 6.7. A more modest increase of
8.5 ± 10.4 points to 41.9 ± 9.5 at seven days post-dose
was reported for the triamcinolone acetonide group and
at eight weeks post-dose, the score (47.1 ± 11.2)
remained below that of the US general population.
In the canakinumab 150 mg group, the greatest
improvements in physical function were seen in
the physical functioning and bodily pain domains (Figure
5a). Mean physical functioning scores rapidly improved
in the canakinumab 150 mg group from 41.5 at baseline
to 80.0 at seven days post-dose (a mean increase of 39.0
points), and exceeded the value for the US general popu-
lation by eight weeks post-dose (86.1 vs 84.2 for the US
general population). Similar improvements were seen in
mean bodily pain scores in the canakinumab 150 mg
g r o u pf r o m3 6 . 0a tb a s e l i n et o7 2 . 2a ts e v e nd a y sp o s t -
dose (a mean increase of 35.6 points) and 86.6 at eight
weeks post-dose (vs 75.2 for the US general population).
More modest and slower improvements were observed in
the triamcinolone acetonide group and scores remained
below those of the US general population at eight weeks
post-dose (Figure 5b).
Improvements in mental well-being accompanied
these changes in physical health. Mean MCS values
increased in all treatment groups and exceeded that of
the US general population at eight weeks post-dose in
all canakinumab groups and approached that of the US
general population for the triamcinolone acetonide
group (mean ± SD at eight weeks post-dose: canakinu-
mab, 50.6 ± 8.2 to 53.3 ± 7.4; triamcinolone acetonide,
49.1 ± 11.1). Improvements from baseline to eight
weeks post-dose were greater in all canakinumab
groups compared with triamcinolone acetonide (5.1 ±
10.1 to 9.5 ± 13.2 vs 4.9 ± 15.7). In the canakinumab
150 mg group, improvements were seen in all indivi-
dual domains, and the greatest improvement was seen
Figure 2 Percentage of patients experiencing no or mild pain following administration of study medication. Pain assessments made
using a 5-point Likert scale. *P < 0.05 for canakinumab 150 mg vs triamcinolone acetonide 40 mg. CI, confidence interval; LS, least-squares.
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patients receiving canakinumab 150 mg (a) or triamcinolone acetonide (TA) 40 mg (b) and physician’s assessment of joint swelling in patients
receiving canakinumab 150 mg (c) or triamcinolone acetonide 40 mg (d). Physicians assessed inflammation in the target joint using the
following tenderness and swelling scales: tenderness rated as none, ‘no pain’; mild, ‘pain’; moderate, ‘pain and winces’; severe, ‘pain; winces and
withdraws’; and swelling rated as none, ‘no swelling’; mild, ‘palpable’; moderate, ‘visible’; and severe, ‘bulging beyond the joint margins’.
Percentages are rounded to one unit therefore numbers at each time point do not necessarily add to 100. TA, triamcinolone acetonide.
Figure 4 Physician’s and patient’s global assessment of response and clinical signs of inflammation (72 hours post-dose).
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18.8 points from baseline to 81.7 was seen at seven
days post-dose for the canakinumab 150 mg group,
and a further increase to 91.7 was seen at eight weeks
post-dose, which exceeded that of the US general
population (83.3). Improvements in social functioning
were also seen in the triamcinolone acetonide group
but the mean score remained below that of the US
general population at eight weeks post-dose (78.1 vs
83.3) (Figure 5b).
Health Assessment Questionnaire
Mean HAQ scores at baseline were indicative of mild
functional disability and were similar for all groups
except the canakinumab 150 mg group (mean for all
groups except canakinumab 150 mg, 1.03 to 1.28; cana-
kinumab 150 mg, 0.74; P = 0.063). Reductions in disabil-
ity were seen in all canakinumab and triamcinolone
acetonide groups, reflected in reductions in HAQ score
f r o mb a s e l i n eo f0 . 4 6t o0 . 6 7a ts e v e nd a y sp o s t - d o s e
and 0.52 to 0.85 at eight weeks post-dose.
Table 1 Percentage of patients achieving normalization
1 of C-reactive protein levels and serum amyloid A protein levels
Variable Canakinumab
10 mg
N =2 8
Canakinumab
25 mg
N =2 9
Canakinumab
50 mg
N =2 8
Canakinumab
90 mg
N =2 9
Canakinumab
150 mg
N =2 7
Triamcinolone
acetonide 40 mg
N =5 6
CRP
Baseline 4 (14.3) 8 (27.6) 6 (21.4) 6 (20.7) 5 (18.5) 12 (21.4)
3 days post-dose 6 (22.2) 13 (46.4) 9 (34.6) 9 (32.1) 11 (44.0) 19 (35.8)
7 days post-dose 13 (46.4) 21 (72.4)* 16 (57.1) 19 (67.9)* 19 (70.4)* 23 (41.8)
4 weeks post-dose 21 (77.8)* 22 (78.6)* 20 (74.1)* 18 (64.3) 20 (74.1)* 27 (49.1)
8 weeks post-dose 17 (65.4)* 21 (75.0)* 17 (63.0) 21 (75.0)* 22 (81.5)* 23 (42.6)
SAA
Baseline 8 (28.6) 9 (32.1) 9 (32.1) 8 (27.6) 9 (33.3) 23 (44.2)
3 days post-dose 15 (57.7) 14 (50.0) 16 (57.1) 13 (46.4) 13 (48.1) 26 (48.1)
7 days post-dose 19 (67.9) 22 (75.9)* 19 (67.9) 21 (75.0)* 17 (65.4) 25 (47.2)
4 weeks post-dose 24 (88.9)* 24 (82.8) 19 (70.4) 20 (71.4) 18 (69.2) 34 (63.0)
8 weeks post-dose 18 (69.2) 21 (80.8) 18 (69.2) 19 (70.4) 20 (74.1) 30 (57.7)
*P < 0.05 vs triamcinolone acetonide 40 mg.
1Upper limit of normal: 3 mg/L for CRP, 6.7 mg/L for SAA.
CRP, C-reactive protein; SAA, serum amyloid A protein.
Figure 5 Spidergrams showing HRQoL improvement (SF-36 scores): canakinumab 150 mg (A); triamcinolone acetonide 40 mg (B).
Acute version 2 of SF-36, 36-item Short-Form Health Survey; HRQoL, health-related quality of life.
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As reported previously [24], all treatments were gener-
ally well tolerated. There were no deaths and no
patients experienced serious AEs related to the study
drugs or discontinued the study owing to AEs. The inci-
dence of patients with AEs was similar for canakinumab
(59 out of 143 patients, 41.3%) and triamcinolone aceto-
nide (24 out of 57 patients, 42.1%), and all except two
of the AEs were mild or moderate in severity. The inci-
dence of infections was low; 7% of all canakinumab-trea-
ted patients and 7% of those in the triamcinolone
acetonide group. Anti-canakinumab antibodies were
detected in two patients in the canakinumab 150 mg
group. In one patient, antibodies were detected at base-
line, but were absent at the end of the study. In the sec-
ond patient, antibodies were detected at baseline and at
the end of the study. No anti-canakinumab antibodies
were detected in the other treatment groups.
Discussion
Gouty Arthritis causes severe pain and morbidity
[34,35]. In our study, 98% of patients reported having
moderate-to-extreme pain at baseline and 68% of
patients reported having severe or extreme pain; as
reported previously, mean VAS scores at baseline were
66 to 78 mm [24]. These data are in broad agreement
with other studies reporting on the severity of pain dur-
ing an acute flare and indicate clearly that the majority
of patients experience severe pain [36-39]. For example,
two other studies which have assessed pain in patients
with acute Gouty Arthritis using a 5-point Likert scale
have reported that 49 to 53% [38] and 89% of patients
had severe or extreme pain at baseline [36], whereas
two studies which have employed a 0 to 100 mm VAS
reported baseline scores of 59 to 62 mm [37] and 74 to
78 mm during activity [39]. These scores suggest that
pain associated with acute flares is at least as great or
greater than that experienced by patients with osteoar-
thritis (OA) (mean VAS score, 68 mm [40]) or rheuma-
toid arthritis (RA) (mean VAS scores of 64 to 67 mm
[40] and 62 mm [41] have been reported). Rapid effec-
tive pain relief is, therefore, a priority for management
of acute Gouty Arthritis.
In our study, canakinumab treatment produced rapid
and sustained reductions in pain in patients with acute
Gouty Arthritis who were unresponsive or intolerant to,
or contraindicated for NSAIDs and/or colchicine.
Reductions in pain according to Likert scale scores were
seen with all canakinumab doses, with 24 to 67% of
patients having no or mild pain by 24 hours post-dose
(compared with 38% with triamcinolone acetonide), and
reductions in pain in the canakinumab 150 mg group
were significantly greater than those reported for triam-
cinolone acetonide from 48 hours to 7 days post-dose.
These results paralleled those we have previously
reported for our study using the 0 to 100 mm VAS [24].
Pain relief was rapid, with the LS mean reduction in
pain at 48 hours post-dose being 2.0 (according to the
Likert scale) and 58.0 mm (according to the VAS assess-
ment) in the canakinumab 150 mg group.
Comparison of results across different studies necessa-
rily needs to be cautious given differences in study
design and patient population. However, a meaningful
comparison can be made with the results reported by
Janssens et al. who assessed pain relief in a similar
patient population using a 0 to 100 mm VAS scale at
12 hour intervals for up to 90 hours following the first
dose of treatment [37]. In this double-blind study,
patients were randomized to receive prednisolone 35 mg
once daily or naproxen 500 mg twice daily. Pain scores
at baseline were approximately 15 mm less than in our
study, suggesting that pain was slightly more severe in
our study. Reductions in pain score from baseline were
comparable for prednisolone and naproxen at all time
points and were less than those reported in our study
for canakinumab doses of 50 mg or greater or for triam-
cinolone acetonide at the corresponding times. For
example, the mean change from baseline was 10 mm for
prednisolone and 8 mm for naproxen at zero to six
hours [37], and 20 mm for canakinumab 150 mg and
12 mm for triamcinolone acetonide at six hours in our
study. Similarly, at 66 to 78 hours the mean change
from baseline was 42 mm for both prednisone and
naproxen, comparable with the 43 mm change from
baseline observed with triamcinolone acetonide 40 mg
at 72 hours in our study; a change from baseline of
63 mm was observed at 72 hours for canakinumab
150 mg. The robust pain reductions described here are
in contrast to those reported for another inhibitor of
IL-1b signaling in development, which has apparently
failed to demonstrate significant improvements in pain
(relative to a standard regimen of indomethacin) in
patients with acute Gouty Arthritis [42].
Triamcinolone acetonide 40 mg was chosen as the
comparator in this study based on the experience of the
investigators and the fact that in two countries in which
the study was performed, the 40 mg im dose is labelled
as the initial dose or usual dose and higher doses were
not considered to be acceptable to investigators or the
health authorities. Furthermore, according to a recent
survey, 72% of prescriptions for triamcinolone acetonide
in France, Germany and the UK in 2008 to 2009 were
for the 40 mg dosage (IMS Disease Analyser: Prescrip-
tions of triamcinolone acetonide in France, and Ger-
many for August 2009 to August 2010 and in the UK
for December 2008 to December 2009, personal com-
munication). However, there are no comparative trials
t oi n d i c a t et h a tt h e6 0m gd o s ei sm o r ee f f e c t i v et h a n
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triamcinolone acetonide 40 mg is an effective treatment
for acute Gouty Arthritis having at least comparable
efficacy to that reported for prednisolone and naproxen
by Janssens et al. [37]. Thus triamcinolone acetonide
40 mg was an appropriate comparator to use in this study.
The results reported here for canakinumab are in
agreement with accumulating evidence suggesting that
IL-1b, in addition to mediating inflammation, can sti-
mulate pain directly by activating nociceptors (pain
receptors) [43] and indirectly by signaling through com-
plex cascades that upregulate and/or activate other pain
stimulating molecules [44]. Moreover, IL-1b release in
response to injury can contribute to persistent pain by
stimulating neural hyperexcitability and increasing sensi-
tivity to pain (hyperalgesia) [44]. Therefore, inhibition of
IL-1b with canakinumab may lead directly to a reduc-
tion in pain, as well as indirectly through inhibition of
inflammation.
The Special Interest Group for gout outcomes at the
Outcome Measures in Rheumatology Clinical Trials
(OMERACT) recognized the importance of HRQoL mea-
surement in gout and included it as a core domain for
clinical trials for chronic Gouty Arthritis [45]. Undoubt-
edly, the pain associated with acute flares has a severe
impact on quality of life, as was evident in our study and
has been reported previously [17-21,46]. We herein
report the use of the HRQoL instruments SF-36 acute
version and HAQ in acute Gouty Arthritis patients. In
our study, mean baseline scores for all SF-36 physical
domains and for the PCS were considerably lower than
those for the US general population (physical function-
ing, 31 to 42; role-physical, 31 to 53; bodily pain, 24 to
36; PCS, 30 to 36). These scores suggest considerably
reduced physical function and are comparable with those
expected for men in the US general population aged
>75 years, while most of our study population was of
working age with an approximate median age of 50 years.
Baseline scores for HAQ were indicative of moderate dis-
ability, and were in agreement with the reduced physical
function evident from SF-36 scores.
The influence of gouty arthritis on patient HRQoL is
becoming increasingly recognized but still there are lim-
ited data available for HRQoL during an acute flare. Our
results are in agreement with a number of recent studies
using the SF-36 scale to assess the HRQoL of Gouty
Arthritis patients with differing disease severities
[18,19,21,28]. Interestingly, the scores reported in our
study are similar to those reported in two studies using
patients who were intolerant of or refractory to ULT
(who would be expected to have frequent flares) [18,21].
For example, Becker et al. reported a mean SF-36 physi-
cal functioning score of 46.8, a mean role-physical score
of 35.0 and PCS value of 34.2 for a population with a
mean age of 59 years and experiencing 0.6 flares per
month [18], while Strand et al. reported reductions of 30
to 32 points for physical function, role-physical and bod-
ily pain SF-36 domains compared with age- and gender-
matched controls [21]. Furthermore, in our study, all
aspects of mental health were reduced to lower than US
norms and were in agreement with scores reported by
Strand et al. These authors suggested that the HRQoL
for their patient population was comparable with that of
patients suffering from long-standing RA or active sys-
temic lupus erythematosus, and was much lower than
that for patients with OA or cardiac angina [21]. This
outcome provides initial insights into the impact of acute
Gouty Arthritis flares on HRQoL in an acute setting,
which has not been studied so far. Long-term follow up
of HRQoL in Gouty Arthritis patients, using other more
specialized HRQoL questionnaires, such as the EQ-5D,
may yield further insights into the long-term outcomes
of the different treatments in the future.
In all groups, treatment was associated with dramatic
improvements in HRQoL, particularly relating to physi-
cal function, by seven days post-dose. The greatest
improvements were seen in the physical functioning and
bodily pain domains, and were particularly marked in
the canakinumab 150 mg group. By seven days post-
dose, mean scores almost reached or were equivalent to
those for the US general population for the canakinu-
mab 150 mg group on all domains and reached or
exceeded scores for the general population on most
domains by eight weeks post-dose. In contrast, in the
triamcinolone acetonide group, mean scores remained
10 to 20 points below those of the general population at
seven days post-dose and approached those of the gen-
eral population by eight weeks post-dose. This is the
first study to report the impact of anti-inflammatory
therapy on quality of life in patients with acute Gouty
Arthritis and demonstrates the significant value of
potent anti-inflammatory therapy.
We also report that canakinumab achieved rapid
reductions in inflammation. Physician-assessed visible
signs of inflammation in the joint were reduced by
72 hours post-dose following treatment with canakinu-
mab, and greater reductions in joint tenderness and
swelling were observed throughout the study with cana-
kinumab 150 mg compared with triamcinolone aceto-
nide. In addition, treatment with canakinumab 150 mg
was associated with a statistically significant better
response to treatment according to patient global self-
assessment (P = 0.002) and physician global assessment
(P = 0.003) compared with patients treated with triamci-
nolone acetonide. Previous studies of NSAIDs and corti-
costeroids have reported the effects of treatment on
visible signs of inflammation [36,38,47-50]. However,
these studies have used different scales to measure
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we report here.
Rapid reductions in visible signs of inflammation were
accompanied by significant reductions in levels of the
main acute phase inflammatory proteins, CRP and SAA.
By seven days post-dose, CRP and SAA levels were
normalized in 70% (CRP) and 63% (SAA) of patients
receiving canakinumab 150 mg. This supports evidence
indicating that IL-1b contributes to the regulation of the
production of CRP and SAA [51]. By inhibiting the
activity of IL-1b and its generation from pro-IL-1b,
canakinumab decreases the production of CRP and
SAA. This may be clinically important, not only for its
impact on acute Gouty Arthritis and the risk of recur-
rent flares, but also because of the possible role of
elevated CRP and SAA levels and IL-1b in the develop-
ment of cardiovascular disease [52-54]. As Gouty Arthri-
tis may be an independent risk factor for coronary
artery disease [55] and for cardiovascular mortality [56],
reducing the levels of these inflammatory proteins may
be of additional benefit in patients with Gouty Arthritis.
Our study has a number of limitations. First, the study
involved patients who were unresponsive or intolerant to
or contraindicated for NSAIDs and/or colchicine, based
on their physician’s assessment. Physicians made this
assessment based on an interview with the patient and
from the patient’s medical history. We chose to ask phy-
sicians to make these judgments so that the study reflects
routine clinical practice and would provide an insight
into the characteristics of patients for whom physicians
consider standard anti-inflammatory therapy to be inap-
propriate. Second, in this early phase II study the effect
on HRQoL was included as an explorative objective. This
was limited to assessments made in an acute setting
using the acute version 2 of SF-36 and the HAQ. Further
studies including HRQoL assessments targeting longer-
term outcomes and in specific patient populations will be
required in the future. Third, the study was open to
patients who were within five days of the onset of their
flare. Thus by 72 hours post-dose, it could be expected
that the flare would have started to resolve independently
of treatment in some patients. However, the proportion
of patients for whom this could apply was very small as
the majority of patients (81%) entered the study within
three days of onset of flare. Furthermore, the proportion
of patients entering the study within four or five days of
onset of flare was similar across treatment groups. Thus
the differences between canakinumab 150 mg and triam-
cinolone acetonide observed in this study reflect differ-
ences in the efficacy of the two treatments.
Conclusions
Acute Gouty Arthritis flares are often associated with
excruciating pain that can be associated with disability
and reduced physical functioning. The results of this
study indicate that anti-inflammatory therapy with cana-
kinumab 150 mg produces rapid pain relief, relieves
signs and symptoms of inflammation and results in
rapid clinically significant improvements in quality of
life, especially relating to physical function (as assessed
using the SF-36 acute version 2). These results are parti-
cularly important for patients with acute Gouty Arthritis
who are unable to achieve adequate responses to stan-
dard therapies, or to tolerate standard therapies. The
canakinumab 150 mg dose is being investigated further
in ongoing phase III clinical trials.
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